Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report.

Medicine - 30 Sept 2022

Lai Yi-Hsuan, Tung Kai-Che, Chen San-Chi

Abstract excerpt

RATIONALE: To date, there is no actionable gene has been discovered in hepatocellular carcinoma (HCC). Tumor cells with DNA damage response and repair (DDR) gene loss-of-function mutation is sensitivity to poly-ADP-ribose polymerase (PARP) inhibitors and platinum chemotherapy in ovarian, prostate and pancreatic cancers. There is a case report demonstrated the efficacy of PARP inhibitor for BRCA2 mutation that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Diphosphate Ribose
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Fanconi Anemia Complementation Group A Protein

Share to Phthalazines

Share to Piperazines

Share to Platinum

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36181052
DOI: 10.1097/MD.0000000000030719
PMCID: PMC9524966

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Durable response to olaparib combined low-dose cisplatin in advanced hepatocellular carcinoma with FANCA mutation: A case report.PMID 36181052Read ↗

Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.Semantic proximity Read ↗

Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients.Semantic proximity Read ↗

Exceptional Response to Olaparib: A Case Report of Metastatic Esophageal Squamous Cell Carcinoma in a Patient With Fanconi Anemia, Germline FANCA Mutation, and Somatic BRCA2 Mutations.Semantic proximity Read ↗

Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells.Semantic proximity Read ↗

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)Semantic proximity Read ↗

Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.Semantic proximity Read ↗

Clinical value of identifying genes that inhibit hepatocellular carcinomas.Semantic proximity Read ↗

Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.